TRAIL-R: A Potential Drug Target and Biomarker for Cancer and Autoimmune Diseases

Target Name: Tumor Necrosis Factor Receptor Superfamily Member 10 (TRAIL-R)

NCBI ID: P38440

Tumor Necrosis Factor Receptor Superfamily Member 10 (TRAIL-R)

Other Name(s): Tumor Necrosis Factor Receptor Superfamily Member 10 | TNF-related apoptosis-inducing ligand receptor | Death receptor | TRAIL-R | TRAIL receptor

TRAIL-R: A Potential Drug Target and Biomarker for Cancer and Autoimmune Diseases

Tumor Necrosis Factor Receptor Superfamily Member 10 (TRAIL-R) is a protein that is expressed in a variety of tissues throughout the body, including the liver, spleen, thymus, and pancreas. It is a member of the Tumor Necrosis Factor Receptor Superfamily, which is a family of cytokines that play a crucial role in the immune response and tissue repair.

TRAIL-R is a 21-kDa protein that is composed of a single transmembrane domain and a cytoplasmic tail. It has been shown to play a role in a variety of cellular processes, including inflammation, autophagy, and cell death.

One of the most promising aspects of TRAIL-R is its potential as a drug target. Because TRAIL-R is involved in a wide range of cellular processes that are important for human health, it is an attractive target for the development of new treatments for a variety of diseases.

One of the ways that TRAIL-R is being targeted for drug development is through its role in cancer. Cancer is a leading cause of death in the world, and there is a strong need for new treatments that can effectively target cancer cells. TRAIL-R has been shown to be involved in the regulation of cancer cell growth and survival, and it is possible that it could be used as a drug to inhibit the growth of cancer cells.

Another potential use for TRAIL-R is its role in autoimmune diseases. Autoimmune diseases are a group of conditions in which the immune system attacks the body's own tissues, leading to inflammation and damage. TRAIL-R is involved in the regulation of the immune response, and it is possible that it could be used as a drug to treat autoimmune diseases.

In addition to its potential uses in cancer and autoimmune diseases, TRAIL-R is also being studied for its potential as a biomarker. Tumor necrosis factor receptor superfamily member 10 is a protein that is expressed in a variety of tissues throughout the body, including the liver, spleen, thymus, and pancreas. Therefore, it is possible that TRAIL-R could be used as a biomarker for a variety of diseases, including cancer and autoimmune diseases.

Overall, Tumor Necrosis Factor Receptor Superfamily Member 10 (TRAIL-R) is a protein that is expressed in a variety of tissues throughout the body and is involved in a wide range of cellular processes. Its potential as a drug target and biomarker make it an attractive target for further research and development.

Protein Name: Tumor Necrosis Factor Receptor Superfamily Member 10 (TRAIL-R) (nonspecified Subtype)

The "Tumor Necrosis Factor Receptor Superfamily Member 10 (TRAIL-R) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Tumor Necrosis Factor Receptor Superfamily Member 10 (TRAIL-R) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets